ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.52
-0.17%
US Tech 100
17,554.00
-0.27%
S&P 500
5,187.67
0.00%
US Dollar vs CAD
1.37335
0.04%
Bitcoin
61,081.42
-0.17%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX argenx SE

349.00
-37.08 (-9.60%)
Pre Market
Last Updated: 04:17:31
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
argenx SE ARGX NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-37.08 -9.60% 349.00 04:17:31
Open Price Low Price High Price Close Price Previous Close
386.08
more quote information »

Recent News

Date Time Source Heading
5/09/202400:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
5/08/202405:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
5/07/202416:30GLOBEargenx announces results of Annual General Meeting of..
5/07/202400:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
5/02/202400:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
4/16/202400:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
3/27/202401:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
3/26/202415:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
3/26/202401:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
3/08/202405:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
3/07/202415:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
2/29/202415:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/29/202400:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
2/26/202400:00GLOBEargenx to Present at Upcoming Investor Conferences
2/22/202400:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
2/20/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/20/202400:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
1/18/202405:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/18/202400:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
1/08/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/08/202400:00GLOBEargenx Highlights 2024 Strategic Priorities
1/02/202400:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
12/20/202311:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
12/20/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/20/202300:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
11/28/202310:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
11/28/202306:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
11/28/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/28/202300:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
11/17/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/16/202306:40GLOBEargenx Announces European Commission Approval of..
11/01/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/01/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
10/31/202308:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/31/202301:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
10/24/202300:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
9/27/202315:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
9/21/202307:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
9/21/202300:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
9/15/202300:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
8/30/202300:00GLOBEargenx to Present at Upcoming Investor Conferences
7/27/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
7/27/202300:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
7/24/202315:30GLOBEargenx announces closing of global offering
7/20/202315:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
7/20/202300:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
7/19/202316:58GLOBEargenx announces full exercise of underwriters’ option to..
7/18/202320:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
7/17/202315:58DJNArgenx Launches $750 Million Global Offering
7/17/202315:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]

Your Recent History

NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved